ANI Pharmaceuticals (NASDAQ:ANIP) Raised to “B” at TheStreet

TheStreet upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a c+ rating to a b rating in a research report released on Thursday, November 16th.

ANIP has been the subject of a number of other reports. Zacks Investment Research raised ANI Pharmaceuticals from a hold rating to a buy rating and set a $71.00 target price for the company in a report on Tuesday, November 7th. BidaskClub cut ANI Pharmaceuticals from a hold rating to a sell rating in a report on Saturday, August 5th. Canaccord Genuity reaffirmed a buy rating and set a $66.00 price target (up from $60.00) on shares of ANI Pharmaceuticals in a report on Monday, October 16th. Finally, ValuEngine cut ANI Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, November 14th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $68.25.

Shares of ANI Pharmaceuticals (ANIP) opened at $70.67 on Thursday. ANI Pharmaceuticals has a 52-week low of $42.23 and a 52-week high of $74.70. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $823.52, a P/E ratio of 21.10 and a beta of 2.90.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The business had revenue of $48.16 million during the quarter, compared to analysts’ expectations of $48.12 million. During the same period in the prior year, the firm posted $1.09 EPS. ANI Pharmaceuticals’s quarterly revenue was up 25.0% compared to the same quarter last year. sell-side analysts expect that ANI Pharmaceuticals will post 3.59 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in ANIP. BNP Paribas Arbitrage SA increased its holdings in ANI Pharmaceuticals by 44.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock valued at $101,000 after purchasing an additional 664 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its stake in shares of ANI Pharmaceuticals by 132.0% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 2,390 shares during the period. SG Americas Securities LLC acquired a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at $197,000. Stevens Capital Management LP acquired a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at $207,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at $210,000. 54.96% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “ANI Pharmaceuticals (NASDAQ:ANIP) Raised to “B” at TheStreet” was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://weekherald.com/2017/12/04/ani-pharmaceuticals-inc-anip-upgraded-to-b-at-thestreet.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply